Related Experiment Video
Updated: May 21, 2026
07:57
Assessing Whole-Body Lipid-Handling Capacity in Mice
Published on: November 24, 2020
The Underlying Mechanisms for Olanzapine-induced Hypertriglyceridemia
Hiroki Adachi1, Hidekatsu Yanai, Yuji Hirowatari
1Department of Internal Medicine, National Center for Global Health and Medicine, Kohnodai Hospital, Chiba 272-8516, Japan.
Journal of Clinical Medicine Research
|June 22, 2012
Summary
Olanzapine treatment for bipolar disorder can cause severe hypertriglyceridemia, linked to very-low-density lipoprotein changes. Stopping olanzapine improved inflammation and adiponectin levels, suggesting their role in this metabolic disorder.
Area of Science:
- Pharmacology
- Metabolic Disorders
- Psychiatry
Background:
- Olanzapine is an effective antipsychotic for schizophrenia and bipolar disorder.
- Metabolic disturbances, including hypertriglyceridemia, are known side effects.
- This study investigates a specific case of olanzapine-induced hypertriglyceridemia.
Observation:
- A patient with bipolar disorder developed severe hypertriglyceridemia during olanzapine treatment.
- Lipid metabolism parameters were measured to identify contributing factors.
- Very-low-density lipoprotein (VLDL) was identified as a key factor.
Findings:
- Olanzapine-induced hypertriglyceridemia is significantly associated with VLDL.
- Discontinuation of olanzapine led to a decrease in high-sensitivity C-reactive protein (hs-CRP).
- Adiponectin levels increased after olanzapine cessation.
Implications:
- Inflammation and reduced adiponectin may play a role in olanzapine-induced hypertriglyceridemia.
- Monitoring lipid profiles, particularly VLDL, is crucial for patients on olanzapine.
- Further research into the mechanisms linking olanzapine, inflammation, adiponectin, and lipid metabolism is warranted.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...